Climb Bio reports Q2 2026 results, sets CLYM116 R&D event and Phase 2 start

Climb Bio, Inc. reported financial results for the quarter ended June 30, 2026 on August 6, 2026. The company will host a webcast on September 3, 2026 to review initial Phase 1 PK/PD data and development plans for CLYM116 in IgA nephropathy (IgAN).¹ Climb Bio had already presented initial CLYM116 Phase 1 safety data and translational PK/PD modeling at the European Renal Association Congress in June 2026, describing a favorable initial safety profile.¹ The company anticipates additional Phase 1 data at a medical meeting in the fourth quarter of 2026.¹

A partnered Phase 1/2 study run by Beijing Mabworks Biotech Co., Ltd. is enrolling, with Phase 2 dosing of IgAN patients expected to begin in the third quarter of 2026.¹

For budoprutug, enrollment is ongoing in the second cohort (600 mg) of the PrisMN Phase 2 trial in primary membranous nephropathy, with initial data including preliminary B-cell and anti-PLA2R findings from the low-dose cohort expected at a medical meeting in the fourth quarter of 2026.¹ In immune thrombocytopenia, initial Phase 1b data presented at the European Hematology Association Congress in June 2026 showed favorable safety and tolerability at 250 mg and 500 mg, and robust B-cell depletion with encouraging platelet responses at 250 mg.¹ Additional data from 500 mg and 1000 mg cohorts are expected in the fourth quarter of 2026.¹ The company also reported dosing the first patient in a China Phase 1b/2a SLE trial, alongside ongoing enrollment in a global Phase 1b SLE trial.¹ Global SLE safety and biomarker data are expected in the fourth quarter of 2026.¹

On the balance sheet, Climb Bio completed a private placement on April 29, 2026 generating about $110 million in gross proceeds, which it said extends cash runway into the second half of 2028.¹ Cash, cash equivalents and marketable securities totaled $239.2 million as of June 30, 2026, which the company said is expected to fund operations into the second half of 2028.¹